PPH
VanEck Pharmaceutical ETF
Price Chart
Latest Quote
$102.53
-1.71 (-1.64%)
Current Price
| Previous Close | $104.24 |
| Open | $104.28 |
| Day High | $104.28 |
| Day Low | $101.79 |
| Volume | 825,451 |
Fund Information
| Quarterly Dividend / Yield | N/A / 2.06% |
| Shares Outstanding | 11.55M |
| Net Assets | $941.75M |
| Expense Ratio | 0.36% |
| Category | Health |
| Fund Family | VanEck |
| Net Asset Value | $102.58 |
| Premium/Discount | -0.05% |
| Quarterly Dividend Yield | 2.06% |
| P/E Ratio | 23.20 |
| Exchange | NGM |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $104.54 |
| SMA50 | $102.94 |
| SMA200 | $100.07 |
| RSI | 43.70 |
| ATR | 1.9664 |
| Rel Volume | 2.81 |
Performance History
| Week | -4.36% |
| Month | +0.07% |
| Quarter | +1.34% |
| 6 Months | +2.13% |
| YTD | -0.34% |
| Year | +18.90% |
| 3 Years | +40.48% |
| 5 Years | +51.68% |
| 10 Years | +115.82% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $102.53 | 825,400 |
| 2026-06-17 | $104.24 | 354,100 |
| 2026-06-16 | $105.09 | 80,700 |
| 2026-06-15 | $105.36 | 452,600 |
| 2026-06-12 | $106.47 | 69,100 |
| 2026-06-11 | $107.20 | 198,500 |
| 2026-06-10 | $105.29 | 505,500 |
| 2026-06-09 | $105.89 | 307,900 |
| 2026-06-08 | $104.66 | 652,600 |
| 2026-06-05 | $105.75 | 674,000 |
| 2026-06-04 | $105.02 | 192,100 |
| 2026-06-03 | $101.55 | 153,600 |
| 2026-06-02 | $101.22 | 126,500 |
| 2026-06-01 | $102.28 | 102,400 |
| 2026-05-29 | $104.74 | 642,100 |
| 2026-05-28 | $105.71 | 55,800 |
| 2026-05-27 | $104.81 | 104,600 |
| 2026-05-26 | $104.13 | 136,100 |
| 2026-05-22 | $104.99 | 46,700 |
| 2026-05-21 | $103.80 | 193,700 |
| 2026-05-20 | $102.60 | 125,400 |
| 2026-05-19 | $102.46 | 215,400 |
About VanEck Pharmaceutical ETF
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
đ° Latest News
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
Zacks âĸ 2026-06-10T16:00:00Z
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Zacks âĸ 2026-06-05T10:20:02Z
Even If Eli Lilly Stock Continues to Shine, Stay Away from This Pharmaceutical ETF
Barchart âĸ 2026-06-02T19:02:50Z
Sickly Healthcare Stocks Are Perking Up. For Contrarian Investors, Buying Now Could Be Just the Remedy to Protect Your Portfolio.
Barchart âĸ 2026-05-24T12:30:02Z
AbbVie Stock: Is Wall Street Bullish or Bearish?
Barchart âĸ 2026-05-11T11:54:54Z
Healthcare ETFs in Spotlight Amid Eli Lily's $2.8B AI Drug Move
Zacks âĸ 2026-03-30T14:40:00Z
PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026
24/7 Wall St. âĸ 2026-03-28T11:15:33Z
FDA Clears NVO's Higher Dose of Wegovy: Diversify With These Health ETFs
Zacks âĸ 2026-03-23T15:27:00Z
Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook
Zacks âĸ 2026-02-04T14:30:00Z
VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion
24/7 Wall St. âĸ 2026-01-23T15:36:40Z
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.